MTOR and neoplasm: On the contrary, the tumor feedback mechanisms to some well-recognized tumor drugs, such as, phosphatidylinositol-3-kinase (PI3K) and the mammalian target of rapamycin (mTOR)—the PI3K/mTOR signaling inhibitors (Stratikopoulos and Parsons, 2016), and resistance to anti-mitotic agent (Birhan and Chanie, 2015; Report et al., 2012) currently became the critical therapeutic issues.